Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2010-10-28. The firm operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
Who is the CEO of Sihuan Pharmaceutical Holdings Group Ltd?
Dr. Weicheng Guo is the Executive Deputy Chairman of the Board of Sihuan Pharmaceutical Holdings Group Ltd, joining the firm since 2006.
What is the price performance of SHPHY stock?
The current price of SHPHY is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Sihuan Pharmaceutical Holdings Group Ltd?
Sihuan Pharmaceutical Holdings Group Ltd belongs to Pharmaceuticals industry and the sector is Health Care
What is Sihuan Pharmaceutical Holdings Group Ltd market cap?
Sihuan Pharmaceutical Holdings Group Ltd's current market cap is $0
Is Sihuan Pharmaceutical Holdings Group Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Sihuan Pharmaceutical Holdings Group Ltd, including 3 strong buy, 2 buy, 1 hold, 0 sell, and 3 strong sell
